Dr. Larry Mahan attended the Park City Epilepsy Conference
LONDON, ONTARIO October 10, 2019 -- Dr. Larry Mahan attended the Park City Epilepsy Conference held in Park City, UT (Oct. 6-9) on behalf of OB Pharmaceuticals to share the company's newest preclinical findings regarding its lead compound TD567 in novel models of traumatic brain injury induced seizures. Additionally Dr. Mahan met with members of the National Institute of Neurological Disorders and Stroke's Epilepsy Therapy Screening Program (NINDS ETSP) to receive updates on the progress of the company's compounds undergoing evaluation in the ETSP and to plan the next set of analyses. Potential academic research collaborations were discussed with some of the conference presenters that might offer additional unique insights in TD567's antiepileptic and antiepileptogenic properties.
About the CURE-Sponsored Park City Epilepsy Conference
This unique meeting hosted by the University of Utah brings trainees, junior investigators, and established researchers together with leaders in the field of epilepsy research. Presenters discuss cutting-edge approaches to transforming epilepsy therapy, exploring state of the art neuroscience as it is being applied to therapy development.
About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.